benserazide has been researched along with Infarction, Middle Cerebral Artery in 3 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Delayed treatment of patients with stroke with levodopa/benserazide contributes to enhanced functional recovery, but the mechanisms involved are poorly understood." | 7.78 | Levodopa treatment improves functional recovery after experimental stroke. ( Kuric, E; Ruscher, K; Wieloch, T, 2012) |
| "Delayed treatment of patients with stroke with levodopa/benserazide contributes to enhanced functional recovery, but the mechanisms involved are poorly understood." | 3.78 | Levodopa treatment improves functional recovery after experimental stroke. ( Kuric, E; Ruscher, K; Wieloch, T, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuric, E | 3 |
| Ruscher, K | 3 |
| Wieloch, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475] | Phase 4 | 39 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for benserazide and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Reduction of rat brain CD8+ T-cells by levodopa/benserazide treatment after experimental stroke.
Topics: Animals; Antiparkinson Agents; Benserazide; Brain; CD8-Positive T-Lymphocytes; Chemokine CXCL1; Infa | 2014 |
Dynamics of major histocompatibility complex class II-positive cells in the postischemic brain--influence of levodopa treatment.
Topics: Animals; Antigen-Presenting Cells; Benserazide; Brain; Cytokines; Disease Models, Animal; Dopamine A | 2014 |
Levodopa treatment improves functional recovery after experimental stroke.
Topics: Animals; Antiparkinson Agents; Astrocytes; Benserazide; Blotting, Western; Cell Hypoxia; Cells, Cult | 2012 |